Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 9/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.49 |
| ▸ | F2R | P25116 | 1/20 | 0.49 |
| ▸ | YAP1 | P46937 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7499589 | 0.89 | ITGB3 (0.49) | ITGB3ITGA2BF2RYAP1 | |
| SCHEMBL7500180 | 0.86 | ITGB3 (0.48) | ITGB3ITGA2BF2RYAP1 | |
| SCHEMBL7438635 | 0.86 | ITGB3 (0.41) | ITGB3ITGA2BYAP1KMT2AHTT | |
| SCHEMBL7498595 | 0.86 | ITGB3 (0.48) | ITGB3ITGA2BF2RKMT2AHTT | |
| SCHEMBL7498599 | 0.86 | KMT2A (0.46) | ITGB3ITGA2BF2RKMT2AHTT | |
| SCHEMBL7500224 | 0.86 | ITGB3 (0.53) | ITGB3ITGA2BF2R | |
| SCHEMBL7504291 | 0.84 | ALDH1A1 (0.52) | ITGB3ITGA2BF2RNPC1 | |
| SCHEMBL7500231 | 0.83 | ITGB3 (0.45) | ITGB3ITGA2BF2RKMT2AHTT | |
| Hydrochloric Acid SCHEMBL7498646 | 0.82 | ITGB3 (0.59) | ITGB3ITGA2BF2R | |
| SCHEMBL7446210 | 0.81 | ITGB3 (0.60) | ITGB3ITGA2BF2RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380215-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES CAUSED BY THROMBUS FORMATION SUCH AS ARTERIAL THROMBOSIS, ARTERIAL SCLEROSIS, ISCHEMIC HEART DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2002-04-30 | — | — | US | disclosed |
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-1106606-A2 | N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-13 | — | — | EP | disclosed |
| WO-1995008536-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | F13B, FGB, TGFB1 | ITGB3 52/4885ITGA2B 14/4885F2R 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.